Vaxess Technologies

Vaxess Technologies, Inc., founded by four Harvard graduate students, is a Massachusetts-based biotechnology firm dedicated to revolutionizing vaccine delivery. Their core mission is to enhance global vaccine access through the MIMIX sustained dermal delivery platform, which offers high temperature stability, improved efficacy, and simplified administration. Vaxess envisions a future where vaccines and therapeutics can be self-administered without needles or refrigeration, making healthcare more convenient and accessible, particularly in low-resource settings.

Notable affiliates include the founding team from Harvard, and the company has attracted significant attention from investors in the biotech sector. Key achievements include the development of their innovative MIMIX platform, which has the potential to transform vaccine and therapeutic delivery worldwide. Vaxess's impact lies in its potential to make healthcare more equitable by addressing logistical challenges in vaccine distribution and administration, ultimately aiming to improve public health outcomes on a global scale.